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Curcumin has 
shown some 
benefi t for 
rheumatoid 
arthritis, 
psoriasis, and 
irritable bowel 
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 Does turmeric relieve 
infl ammatory conditions?
EVIDENCE-BASED ANSWER
A   yes, but data aren’t plentiful. Lim-   ited evidence suggests that turmeric 
and its active compound, curcumin, are ef-
fective for rheumatoid arthritis and other 
infl ammatory conditions (strength of recom-
mendation [SOR]: C, primarily low-quality 
cohort studies with small patient numbers). 
Curcumin has shown limited benefi t 
for patients with psoriasis, infl ammatory 
bowel disease (IBS), infl ammatory eye dis-
eases, familial adenomatous polyposis, 
and kidney transplantation (SOR: B, small, 
short randomized controlled trials [RCTs]).
No evidence indicates that curcumin 
helps patients with human immunodefi -
ciency virus (HIV) (SOR: B, single RCT).
Evidence summary
Although extensive in vitro and animal stud-
ies have analyzed the eff ect of curcumin on 
infl ammation and infl ammatory mediators 
(including inhibition of lipoxygenase, cyclo-
oxygenase-2, leukotrienes, thromboxane, 
prostaglandins, and tumor necrosis factor),1 
few human studies have looked at patient-
oriented outcomes. 
❚ Rheumatoid arthritis. One very small 
(N=18) double-blind crossover study showed 
a statistically signifi cant improvement in 
morning stiff ness, walking time, and joint 
swelling in rheumatoid arthritis patients tak-
ing curcumin.2 
❚ Psoriasis. A cohort study demonstrated 
that curcumin applied topically in a gel for-
mulation to patients with psoriasis resulted 
in either resolution or reduction in psoriatic 
plaques after 8 weeks of treatment.3
❚ IBS. Two studies have found curcumin 
to have a positive eff ect on patients with IBS. A 
cohort study (N=10) of patients with ulcerative 
colitis or Crohn’s disease demonstrated symp-
tomatic improvement (more formed stools, 
less frequent bowel movements, and less ab-
dominal pain and cramping) after consuming 
curcumin for 2 and 3 months, respectively.4 A 
randomized, double-blind, multicenter trial 
(N=89) showed that 6 months of daily cur-
cumin improved the clinical activity index and 
maintained remission in patients with ulcer-
ative colitis.5
❚ Infl ammatory eye diseases. A cohort 
study of 32 patients found that curcumin was 
as eff ective as corticosteroids for chronic an-
terior uveitis (as demonstrated by improved 
vision, decreased keratic precipitates, and 
a break of synechiae assessed by slit lamp 
examination).6 Another small cohort study 
(N=5) by the same authors showed that cur-
cumin reduced or resolved infl ammatory or-
bital pseudotumor (as evidenced by reduced 
ocular swelling, normal ocular movements, 
and absence of diplopia).7
❚ Familial adenomatous polyposis. A 
small cohort study (N=5) demonstrated a 
decrease in size and number of adenomas in 
patients with familial adenomatous polyposis 
after a mean of 6 months of treatment with 
curcumin, although patients received querce-
tin concurrently during the treatment period.8 
❚ Kidney transplantation. A cohort study 
followed 43 dialysis-dependent cadaver kid-
ney recipients who had taken curcumin for 
1 month. Investigators observed reduced 
acute rejection and neurotoxicity over the 
course of 6 months.9
❚ HIV. Curcumin didn’t reduce viral load 
or improve CD4 counts in 40 HIV patients 
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in the single study identifi ed in a Cochrane 
Review.10
Dosage and adverse effects
Dosing varied across the studies reviewed in this 
Clinical Inquiry, but generally was 500 to 1000 
mg, 1 to 3 times daily. Curcumin doses as high as 
12,000 mg daily have been given in experimen-
tal settings without signifi cant adverse events. 
Minor gastrointestinal side eff ects, including 
nausea and diarrhea, have been reported.11
Recommendations
Th e National Center for Complementary and 
Alternative Medicine of the National Institutes 
of Health states that little reliable evidence 
exists to support the use of turmeric for any 
health condition because few clinical trials 
have been conducted. Preliminary fi ndings 
from animal and laboratory studies suggest 
that curcumin may have anti-infl ammatory 
and anticancer properties, but these fi ndings 
have not been confi rmed in people.12 JFP
 1.   Chainani-Wu N. Safety and anti-infl ammatory activity of cur-
cumin: a component of turmeric (Curcuma longa). J Altern Com-
plement Med. 2003;9:161-168. 
 2.   Deodhar SD, Sethi R, Srimal RC. Preliminary studies on antirheu-
matic activity of curcumin (diferuloyl methane). Indian J Med 
Res. 1980;71:632-634. 
 3.   Heng MC, Song MK, Harker J, et al. Drug-induced suppression of 
phosphorylase kinase activity correlates with resolution of psori-
asis as assessed by clinical, histological, and immunohistochemi-
cal parameters. Br J Dermatol. 2000;143:937-949. 
 4.   Holt PR, Katz S, Kirshoff  R. Curcumin therapy in infl ammatory 
bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191-2193. 
 5.   Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy 
for ulcerative colitis: randomized, multicenter, double-blind, place-
bo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502-1506. 
 6.   Lal B, Kapoor AK, Asthana OP, et al. Effi  cacy of curcumin in 
the management of chronic anterior uveitis. Phytother Res. 
1999;13:318-322. 
 7.   Lal B, Kapoor AK, Agrawal PK, et al. Role of curcumin in idio-
pathic infl ammatory orbital pseudotumours. Phytother Res. 
2000;14:443-447. 
 8.   Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination 
treatment with curcumin and quercetin of adenomas in famil-
ial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4:
1035-1038. 
 9.   Shoskes D, Lapierre C, Cruz-Correa M, et al. Benefi cial eff ects 
of the biofl avonoids curcumin and quercetin on early function 
in cadaveric renal transplantation: a randomized placebo con-
trolled trial. Transplantation. 2005;80:1556-1559. 
 10.   Liu JP, Manheimer E, Yang M. Herbal medicines for treat-
ing HIV infection and AIDS. Cochrane Database Syst Rev.
2005;(3):CD003937. 
 11.   Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med 
Biol. 2007;595:471-480. 
 12.   National Center for Complementary and Alternative Medicine. 
Herbs at a glance: turmeric. Updated August 12, 2010. Available 
at: http://nccam.nih.gov/health/turmeric/. Accessed October 
11, 2010. 
PRESENTED BY AND
MEDS
Metabolic & Endocrine
Disease Summit
PRESENTED BY:
       Join us for this Interactive, Live 
Event for Primary Care Clinicians
      •  Earn CE/CME credit*
       •  Enhance your ability to treat the growing number of patients 
affected by metabolic and endocrine diseases
       •  Network with fellow primary care clinicians
       •  Empower yourself to fill the void created by the national shortage 
of endocrinologists
For more information go to: 
www.MEDSummit.qhc.com
JULY 28-30, 2011   I   WALT DISNEY WORLD SWAN AND DOLPHIN   I   ORLANDO, FLORIDA
* This program will be submitted 
to the American Academy 
of Nurse Practitioners for 
continuing education credit. 
* This program is not yet 
approved for CME credit. 
Conference organizers 
plan to request 19 hours of 
AAPA Category I CME credit 
from the Physician Assistant 
Review Panel. Total number 
of approved credits yet to be 
determined.
